Apellis Pharmaceuticals Inc’s filing revealed that its Chief Scientific Officer Deschatelets Pascal unloaded Company’s shares for reported $3.74 million on Apr 08 ’24. In the deal valued at $54.17 per share,69,107 shares were sold. As a result of this transaction, Deschatelets Pascal now holds 1,115,983 shares worth roughly $57.47 million.
Then, Sullivan Timothy Eugene sold 4,000 shares, generating $234,640 in total proceeds. Upon selling the shares at $58.66, the Chief Financial Officer now owns 93,338 shares.
Before that, Dunlop A. Sinclair sold 18,681 shares. Apellis Pharmaceuticals Inc shares valued at $1,068,161 were divested by the Director at a price of $57.18 per share. As a result of the transaction, Dunlop A. Sinclair now holds 173,998 shares, worth roughly $8.96 million.
Jefferies upgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Buy from a a Hold in a research note published on February 05, 2024; the price target was increased to $80 from $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid December from “an Overweight” to “an Equal weight”. Goldman began covering APLS with “Buy” recommendation on November 09, 2023. Mizuho started covering the stock on November 02, 2023. It rated APLS as “a Neutral”.
Price Performance Review of APLS
On Monday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -0.56% to $51.50. Over the last five days, the stock has lost -4.29%. Apellis Pharmaceuticals Inc shares have fallen nearly -13.97% since the year began. Nevertheless, the stocks have fallen -34.94% over the past one year. While a 52-week high of $94.75 was reached on 01/09/24, a 52-week low of $19.83 was recorded on 04/12/24. SMA at 50 days reached $61.29, while 200 days put it at $53.21. A total of 2.62 million shares were traded, compared to the trading of 2.0 million shares in the previous session.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 50.17, which if violated will result in even more drops to 48.85. On the upside, there is a resistance level at 52.93. A further resistance level may holdings at 54.37. The Relative Strength Index (RSI) on the 14-day chart is 34.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.47%. Stochastics %K at 22.44% indicates the stock is a holding.
